Joanne Zhongyan Zhang M.D., PhD
About Joanne Zhongyan Zhang M.D., PhD
Joanne Zhongyan Zhang M.D., PhD - Director of Micro and Biology
Joanne Zhongyan Zhang, M.D., PhD, is currently serving as the Director of Micro and Biology. She brings extensive experience to the role, with a background in both clinical medicine and advanced research. Her expertise spans various specialties including cell biology, cardiology, and molecular science. Her work's impact is highlighted by her leadership in diverse research and clinical settings.
Joanne Zhongyan Zhang's Role at Tianjin First Central Hospital
Joanne Zhongyan Zhang dedicated over six years as an attending physician and chief physician at Tianjin First Central Hospital. During this time, she honed her clinical skills and contributed significantly to patient care and medical research. Her leadership roles at the hospital showcased her proficiency in applying her medical knowledge to complex healthcare settings.
Education Background of Joanne Zhongyan Zhang
Joanne Zhongyan Zhang earned her medical degree from Tianjin Medical University, solidifying her foundational knowledge in medicine. She further advanced her education by obtaining a PhD from the Cardiology Division of Internal Medicine and Molecular Science at Osaka University. These academic achievements provided her with a robust platform for her subsequent research and clinical endeavors.
Postdoctoral Fellowship and Research Associateships of Joanne Zhongyan Zhang
Joanne Zhongyan Zhang was a postdoctoral fellow in Cell Biology at Johns Hopkins University, where she expanded her research capabilities. She also served as a research associate in the Cardiology Department at Duke University. These positions allowed her to engage deeply with cutting-edge research and further her expertise in her respective fields.
Joanne Zhongyan Zhang's Contributions to ALS and Cuprizone Studies
Joanne Zhongyan Zhang played a crucial role in the design and execution of pivotal studies related to neurodegenerative diseases. She helped design and personally executed the initial and validated Cuprizone Studies of Clene’s asset, CNM Au8. Additionally, she designed and directed the ALS pilot study that demonstrated Au8's ability to improve motor coordination in the congenic ALS SOD1 G93A mouse model. These contributions have been fundamental in advancing therapeutic research.